Business Context and Reporting Period
Company: The AES Corporation (AES)
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2025
Subject: Non-reliance on previously issued financial statements for the second and third quarters of 2024 due to a restatement of impairment expenses related to the sale of AES Brasil Energia S.A.
Key Financial Metrics and Restatement Details
The filing addresses a correction to previously reported impairment expenses rather than current period performance metrics.
- Restated Periods: Q2 2024 (ended June 30, 2024) and Q3 2024 (ended September 30, 2024).
- Reason for Restatement: Overstatement of impairment expense related to the sale of a 47.3% stake in AES Brasil, caused by incomplete data used in fair value estimations.
- Q2 2024 Adjustment: Impairment expense was overstated by approximately $192 million.
- Q3 2024 Adjustment: Impairment expense was overstated by approximately $5 million.
- Impact on Key Metrics: The restatement does not adversely impact previously reported revenues, operating margin, Net (loss) income, cash flows, or Adjusted EBITDA for the restated periods.
- Full Year 2024 Impact: No effect on full-year 2024 Net Income Attributable to The AES Corporation, Earnings Per Share, Adjusted EBITDA, or Adjusted EPS.
Material Changes and Internal Controls
Material Weakness Identified: Management has identified a material weakness in internal control over financial reporting resulting from the error in estimating fair value for the AES Brasil transaction.
Reporting Status:
- Previously filed Form 10-Q reports for Q2 and Q3 2024 should no longer be relied upon.
- Restated financial statements are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed on March 10, 2025.
- The Company does not intend to file amended Form 10-Q reports for the restated periods.
Guidance, Outlook, and Risks
Management Commentary: The Company has discussed the matter with its independent auditor, Ernst & Young LLP. A remediation plan for the material weakness is described in the 2024 Form 10-K.
Risks and Contingencies:
- Forward-looking statements regarding the remediation of internal control deficiencies and future performance are subject to risks and uncertainties.
- Actual results may differ materially from projections due to factors discussed in the "Risk Factors" and "Management's Discussion & Analysis" sections of the 2024 Form 10-K.
Investor Verification Checklist
- Verify the restated financial figures in the 2024 Form 10-K (filed March 10, 2025) rather than the original Q2 and Q3 2024 Form 10-Q filings.
- Review the specific details of the material weakness in internal controls and the proposed remediation plan in the 2024 Form 10-K.
- Confirm that the $197 million total adjustment ($192M + $5M) to impairment expenses does not alter the company's full-year 2024 bottom-line metrics as stated.
- Monitor future filings for updates on the remediation of the internal control deficiency.